Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Enkephalin Degrading Enzymes: Metalloproteases with High Potential for Drug Development

Author(s): Tejinder Pal Khaket, Jasbir Singh, Pooja Attri and Suman Dhanda

Volume 18, Issue 2, 2012

Page: [220 - 230] Pages: 11

DOI: 10.2174/138161212799040547

Price: $65

Abstract

Enkephalins play a great role in management of pain, blood pressure, hypertension and cardiovascular diseases. Enkephalins are short-lived molecules being rapidly hydrolyzed following their synaptic release by enkephalin degrading enzymes. The inhibitors of enkephalin degrading enzymes are able to prolong the duration of action of enkephalins. This review will focus on the inhibitors of enkephalin degrading enzymes as a novel therapeutic approach for cancer itself and also in cancer and neuropathic pain management with discussion on the present status and future directions for a new class of drugs.

Keywords: Enkephalins, dipeptidylpeptidase-III, aminopeptidase N, neutral endopeptidase, angiotensin converting enzyme, puromycin sensitive enzyme, carboxypeptidase A6 and pain, hypertension, enkephalin degrading enzymes, stress

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy